Effect of M & B 17803A, a new -adrenoceptor blocking agent, on the cardiovascular responses to tilting and to isoprenaline in man.

1. DL-1-(2-acetyl-4-n-butyramidophenoxy)-2-hydroxy-3-isopropylaminopropane hydrochloride (M & B 17803A) was given to four healthy volunteers in single oral doses of up to 300 mg. There were no subjective effects and no significant alterations in the heart rate, systolic and diastolic blood pressure in the seated position or in the forced expiratory volume or in the electrocardiogram within 6 h of the dose. There were no abnormalities in haematological tests and estimations of the serum glutamyloxaloacetic transaminase.2. Oral doses of both M &; B 17803A and propranolol inhibited the increase in heart rate which occurs on tilting from the supine to the 80 degrees head up position. The results suggest that the degree of beta-adrenoceptor blockade produced by M &; B 17803A (100 and 300 mg) is comparable to that of propranolol (10 and 40 mg) respectively. Propranolol is 7.5-10.0 times as potent as M &; B 17803A when compared by this method. There were no significant changes in the systolic or diastolic blood pressure after any of the treatments, in either of the positions studied.3. M &; B 17803A was also effective in inhibiting the increase in heart rate produced by the intravenous infusion of isoprenaline and in two subjects the degree of beta-adrenoceptor blockade produced by M &; B 17803A (300 mg) was comparable to that of propranolol (40 mg). M &; B 17803A is a competitive beta-adrenoceptor blocking agent and the duration of the pharmacological activity of both M &; B 17803A and propranolol appeared to be very similar as assessed by this method.4. In separate experiments with small oral doses of M &; B 17803A no evidence of a selective action on myocardial beta-adrenoceptors was obtained from the study of changes in heart rate and diastolic blood pressure (sphygmomanometric recording).

RCT Entities:   Population Interventions Outcomes